You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

camrelizumab

Showing 1 - 25 of 388
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,

Recruiting
  • Esophageal Cancer by AJCC V8 Stage
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 12, 2023

Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • camrelizumab for Injection
  • (no location specified)
Nov 13, 2023

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

Chordoma, Chemo Effect Trial in Beijing (camrelizumab and apatinib)

Recruiting
  • Chordoma
  • Chemotherapy Effect
  • camrelizumab and apatinib
  • Beijing, Beijing, China
    BEIJING
Nov 14, 2023

TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Camrelizumab Plus Chemotherapy and Famitinib
  • Camrelizumab Plus Chemotherapy
  • (no location specified)
Aug 17, 2023

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Recruiting
  • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jan 4, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)

Recruiting
  • Advanced Gastric Adenocarcinoma
  • camrelizumab
  • Henan, China
    Henan Tumor Hospital
Oct 13, 2022

Advanced Hepatocellular Carcinoma Trial in Guangzhou (adebrelimab, camrelizumab plus apatinib)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • adebrelimab, camrelizumab plus apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Jun 21, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 27, 2023

Immunotherapy, Chemo Trial in Guandong (Camrelizumab)

Recruiting
  • Immunotherapy
  • Chemotherapy
  • Camrelizumab
  • Guandong, Guangdong, China
    Nanfang Hospital, Southern Medical University
Apr 22, 2023

Unresectable/Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib plus camrelizumab and capecitabine)

Recruiting
  • Unresectable/Metastatic Colorectal Cancer
  • Fruquintinib plus camrelizumab and capecitabine
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 19, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Camrelizumab
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Camrelizumab
  • +2 more
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Esophageal Tumors, Esophageal Diseases, Digestive System Tumors Trial (Camrelizumab, Paclitaxel, Platinum)

Not yet recruiting
  • Esophageal Neoplasms
  • +2 more
  • Camrelizumab
  • +3 more
  • (no location specified)
Nov 20, 2022

Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

Not yet recruiting
  • Locally Advanced Biliary Tract Cancer
  • Metastatic Biliary Tract Cancer
  • Camrelizumab and Apatinib Plus GP
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Feb 15, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Jan 27, 2023

Ovarian Clear Cell Carcinoma Trial (Camrelizumab)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • Camrelizumab
  • (no location specified)
Oct 29, 2022

Metastatic Liver Cancer Trial in Shanghai (HAIC?Bevacizumab?Camrelizumab)

Not yet recruiting
  • Metastatic Liver Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 7, 2022

Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Camrelizumab
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Nov 16, 2022

Advanced Hepatocellular Carcinoma Trial in Chengdu (Lenvatinib combined with TACE and Camrelizumab)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Lenvatinib combined with TACE and Camrelizumab
  • Chengdu, Sichuan, China
    HuaXi hospital
Feb 12, 2023

Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)

Recruiting
  • Macrotrabecular Massive Hepatocellular Carcinoma
  • HAIC
  • Camrelizumab plus Apatinib
  • Wuhan, Hubei, China
    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023

Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Camrelizumab
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 25, 2023